NASDAQ
17.03USD
0.00 (0.00%)
We have scored 10 news catalysts on Theravance Biopharma Inc (TBPH) over the past 12 months. The biggest single-day move next to one of them came Nov 11, 2025, when TBPH closed +22.7%: “Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates”. Coverage across the window leans negative (average ticker sentiment −0.12). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
884.2M
P/E
—
EPS
—
Beta
0.17
52W range
13.08-21.03
Day range
17.02–17.07
Open
17.05
Prev close
17.03
Volume
10M
Avg volume
635.4K
Dividend
0.00
IPO
2014-05-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Theravance Biopharma Inc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TBPH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
